We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-4.61%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$4.5B
AUM Growth
-$546M
Cap. Flow
-$309M
Cap. Flow %
-6.85%
Top 10 Hldgs %
82.03%
Holding
109
New
17
Increased
29
Reduced
12
Closed
18

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$24.5M
2
ATH
Athene Holding Ltd. Class A Common Shares
ATH
+$18.5M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$18.4M
4
ZTO icon
ZTO Express
ZTO
+$14.4M
5
CELG
Celgene Corp
CELG
+$11.1M

Top Sells

Rank Stock Value
1
GS icon
Goldman Sachs
GS
+$32.3M
2
BAC icon
Bank of America
BAC
+$19.3M
3
ARRY
Array Biopharma Inc
ARRY
+$16.6M
4
MS icon
Morgan Stanley
MS
+$13.2M
5
APTV icon
Aptiv
APTV
+$10.7M

Sector Composition

Rank Sector Weight
1 Consumer Staples 46.77%
2 Healthcare 25.98%
3 Consumer Discretionary 7.97%
4 Financials 0.43%
5 Industrials 0.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BUFF
1
DELISTED
Blue Buffalo Pet Products, Inc
BUFF
$2.1B 46.67%
87,460,875
– –
LXRX icon
2
Lexicon Pharmaceuticals
LXRX
$1.04B
$795M 17.66%
57,517,977
– –
WW
3
DELISTED
WW International
WW
$337M 7.48%
29,443,300
– –
MET icon
4
CALL
MetLife
MET
$62.3B
$94.3M 2.09%
1,963,500
+1,122,000
+133% +$51.5M
CELG
5
CALL
DELISTED
Celgene Corp
CELG
$81M 1.8%
700,000
– –
REGN icon
6
CALL
Regeneron Pharmaceuticals
REGN
$73B
$66.1M 1.47%
180,000
+80,000
+80% +$30.4M
INCY icon
7
Incyte
INCY
$25.2B
$65.2M 1.45%
650,000
+50,000
+8% +$4.88M
WFC icon
8
CALL
Wells Fargo
WFC
$257B
$55.1M 1.22%
1,000,000
+650,000
+186% +$32.7M
JPM icon
9
CALL
JPMorgan Chase
JPM
$926B
$51.8M 1.15%
600,000
+350,000
+140% +$26.7M
BMY icon
10
CALL
Bristol-Myers Squibb
BMY
$130B
$46.8M 1.04%
800,000
– –
CMG icon
11
CALL
Chipotle Mexican Grill
CMG
$43.9B
$43.4M 0.96%
5,750,000
+2,000,000
+53% +$15.8M
ALXN
12
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
$42.8M 0.95%
350,000
+100,000
+40% +$12.2M
BIIB icon
13
CALL
Biogen
BIIB
$31.4B
$42.5M 0.94%
150,000
– –
BAC icon
14
CALL
Bank of America
BAC
$431B
$35.4M 0.78%
1,600,000
-3,400,000
-68% -$65.5M
FXI icon
15
CALL
iShares China Large-Cap ETF
FXI
$4.31B
$34.7M 0.77%
1,000,000
– –
WMT icon
16
CALL
Walmart Inc
WMT
$905B
$34.6M 0.77%
1,500,000
– –
AGIO icon
17
Agios Pharmaceuticals
AGIO
$2.08B
$31.3M 0.69%
750,000
+350,000
+88% +$18.4M
BMRN icon
18
BioMarin Pharmaceuticals
BMRN
$12B
$29M 0.64%
350,000
+50,000
+17% +$4.3M
BLUE
19
DELISTED
bluebird bio
BLUE
$26.1M 0.58%
32,620
+2,898
+10% +$2.3M
AGIO icon
20
CALL
Agios Pharmaceuticals
AGIO
$2.08B
$25M 0.56%
600,000
+100,000
+20% +$5.25M
ALXN
21
DELISTED
Alexion Pharmaceuticals
ALXN
$24.5M 0.54%
+200,000
New +$24.5M
BABA icon
22
Alibaba
BABA
$275B
$22M 0.49%
250,000
-50,000
-17% -$4.81M
ATH
23
DELISTED
Athene Holding Ltd. Class A Common Shares
ATH
$19.2M 0.43%
+400,000
New +$18.5M
ALNY icon
24
Alnylam Pharmaceuticals
ALNY
$38.3B
$18.7M 0.42%
500,000
-100,000
-17% -$4.19M
IBM icon
25
CALL
IBM
IBM
$214B
$16.6M 0.37%
104,600
– –
1
2 3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q4 2016 Portfolio in Review

As of Q4 2016, Artal Group held 109 positions worth $4.5B, down 11% from $5.05B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Artal Group withdrew a net $309M in Q4 2016, closing 18 positions and reducing 12 holdings. Its most notable exit was Goldman Sachs, an estimated $32.3M position sold in full.

By sector, the portfolio is most concentrated in Consumer Staples at 47% of assets, up from 41% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, Artal Group opened a new position in Alexion Pharmaceuticals worth $24.5M.

  • Artal Group's largest Q4 2016 buy was Alexion Pharmaceuticals: 200,000 shares worth $24.5M.
  • Artal Group added most to Agios Pharmaceuticals in Q4 2016, an estimated $18.4M increase.
  • Artal Group's biggest Q4 2016 reduction was Array Biopharma Inc, cutting an estimated $16.6M.
  • Artal Group fully exited Goldman Sachs in Q4 2016, selling an estimated $32.3M.
  • Artal Group's ten largest holdings make up 82% of its $4.5B portfolio in Q4 2016.
  • Artal Group opened 17 new positions and closed 18 in Q4 2016.
  • Artal Group's portfolio value fell 11% quarter-over-quarter to $4.5B.

Based on Artal Group's 13F filing for Q4 2016, filed 14 Feb 2017.